Just artisan for the MAA, I think, but despite what some bears say, NICE is interested in things like manufacturing cost reduction for reimbursement calculations, and I think the plan is to run EDEN clinical parallel to Artisan commercial for comparability testing, so what that means regarding signing off for EDEN initially is above my knowledge. I’m opining the cancer drug fund may play a temporary reimbursement role to achieve this transitional testing purpose on a limited population per year. Just guessing.
Market Data 
Markets 
AI
